Clinical trials: Alzheimer Dementia
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is currently being developed for the treatment…
- Trial name
- NCT02130661
- Testing
- Rilapladib 25 mg, Rilapladib 250 mg, Itraconazole
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dementia, Alzheimer's Disease
Comparative Research of Alzheimer's Disease Drugs
Conduct a comparative effectiveness clinical trial of medication treatment for behavioral symptoms of Alzheimer's disease in a group of real-world memory care clinics with enhanced access to the Indiana Network for Patient Care.
- Trial name
- COMET-AD (NCT01362686)
- Testing
- Donepezil, Galantamine, Rivastigmine
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Indiana University
Dementia of the Alzheimer's Type
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
This is a long-term-safety roll-over extension study for a Phase II Study (Protocol CPC-001-07).
- Trial name
- NCT02434666
- Testing
- CPC-201
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Alzheimer Disease
Memory Functions in Mild Alzheimer's Disease
The overall objective of this project is to examine the effects of non-invasive brain stimulation on episodic memory performance
- Trial name
- MemStim-lab (NCT04785053)
- Testing
- transcranial alternating current stimulation (tACS)
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Hebrew SeniorLife
Alzheimer Dementia (AD), Diabete Type 2
Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier…
- Trial name
- PETTAU (NCT07482072)
- Testing
- [18F]FDG PET, [11C]PIB
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Stroke, Stroke (CVA) or TIA
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)
Stroke is a major cause of death and disability worldwide, frequently resulting in persistent cognitive deficits among survivors.
- Conditions
- Stroke, Stroke (CVA) or TIA, Dementia, Vascular, Cerebrovascular Disorders
- Trial name
- IC3 (NCT05885295)
- Testing
- MRI brain, Blood tests, cognitive assessments
- Where
- United Kingdom
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Alzheimer's Disease
A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
This study will assess the pharmacokinetics of MK-8931, a ß-secretase inhibitor, in participants with renal insufficiency. In Part 1 of the study, pharmacokinetics of MK-8931 in participants with severe renal disease and in…
- Trial name
- NCT01537757
- Testing
- MK-8931
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease, Parkinson Disease
Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device
Primary Objective: The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device.
- Conditions
- Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration
- Trial name
- MemorEM (NCT07222605)
- Testing
- MemorEM
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- eQ8Health Corporation d/b/a CareONE Concierge
Alzheimer's Disease
Electroconvulsive Therapy for Treatment of Alzheimer´s Disease
Electroconvulsive therapy (ECT) induces a cerebral seizure by electrical stimulation under general anesthesia and muscle relaxation, is regarded as a highly efficient (for specific and severe psychiatric disorders) and extremely…
- Trial name
- ECTAD (NCT02438202)
- Testing
- Thymatron IV device (Somatics)
- Volunteers
- 15 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Alzheimer Disease, Dementia
Predictors of Cognitive Decline in Normal Aging
The goal of this project is to develop an early diagnostic test for Alzheimer's disease (AD) by monitoring loss of neurons and brain size reductions over a period of five years.
- Trial name
- NCT00094939
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer's Disease and Related Dementias
Pilot Testing Dementia-Enhanced Training and Tool for Home Hospice Clinicians
The purpose of this study is to pilot test the feasibility, acceptability, and preliminary efficacy of a clinically useful, inclusive dementia-enhanced training and tool for use by home hospice clinicians to improve care and…
- Trial name
- EDITH-HC (NCT05719077)
- Testing
- EDITH-HC
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Alzheimer Disease
A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)
The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured…
- Trial name
- NCT00004845
- Testing
- Rofecoxib, Naproxen
- Where
- 40 sites in United States
- Sponsor
- National Institute on Aging (NIA)
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Alzheimer's Disease
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.
- Trial name
- NCT01703702
- Testing
- florbetapir (18F)
- Where
- 57 sites in United States, France and 1 more
- Volunteers
- 641 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer´s Disease
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD).
- Trial name
- AD Biomarker (NCT07741526)
- Testing
- NPI-001
- Where
- 4 sites in Denmark, Iceland
- Volunteers
- 33 people
- Sponsor
- Arctic Therapeutics
Alzheimer Disease
Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease
The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00481520
- Testing
- SAM-531
- Where
- 7 sites in United States
- Volunteers
- 72 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Alzheimer Disease, Hearing Loss
Early Age-Related Hearing Loss Investigation (EARHLI)
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention.
- Conditions
- Alzheimer Disease, Hearing Loss, Cognitive Impairment
- Trial name
- EARHLI (NCT06174038)
- Testing
- Hearing Intervention, Health Education Intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Alzheimer Disease
PDE5 Inhibitor for Alzheimer's Disease
Alzheimer's disease is the most common cause of dementia in the elderly population. The disease is characterised by the presence of abnormal proteins in the brain, primarily β-amyloid (Aβ) and tau.
- Trial name
- NCT07172815
- Testing
- tadalafil
- Volunteers
- 244 people
- Sponsor
- Imperial College London